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Background: Agitation is a common and distressing symptom affecting large numbers of people with dementia and 
impacting significantly on quality of life. In the absence of safe, effective pharmacological therapies there is a need for 
evidence-based, cost-effective first-line non-drug treatments. A factorial study has enabled us to optimize the intervention, 
which we have now evaluated in a large cluster RCT. Methods: Design: A randomized controlled cluster trial comparing the 
WHELD intervention with treatment as usual in 69 UK nursing homes Participants: Nursing home residents with dementia 
Intervention: All nursing homes receiving the WHELD intervention received staff training in person-centered care (PCC), 
social interaction (SoI) and antipsychotic review (AR) followed by ongoing delivery through a care staff champion model. 
Main Outcome Measures: Quality of life (DEMQOL-proxy), agitation (Cohen Mansfield Agitation Inventory), 
neuropsychiatric symptoms (NPI), antipsychotic use and pain (Abbey Pain Scale). Results: Are presented as weight mean 
difference in change with 95% Confidence Intervals (CI). Intervention costs were calculated using published cost function 
figures and compared with usual costs. Results: 971 people were randomized to WHELD or treatment as usual. WHELD 
conferred a significant improvement in agitation (CMAI 8.63 95% CI 1.06 to 16.19, p¼0.025). There was also a numerical 
non-significant benefit in quality of life (DEMQOL proxy 10.93 95% CI -2.82 to 24.68, p¼0.12), which became significant in 
people with agitation (DEMQOL proxy 16.56 95% CI 0.35-32.78, p¼0.045). An exploratory analysis showed benefit in the 
participants with moderate or severe pain at baseline (Abbey Pain Scale 2.93 95% CI -2.46 -.49, p¼0.003). Antipsychotic 
drug prescribing was stable in both treatment groups. The WHELD intervention reduced cost compared to treatment as 
usual, and the benefits achieved were therefore associated with a cost saving. Conclusions: This is the largest RCT of a non-
pharmacological intervention for people with dementia in nursing homes. WHELD conferred improvements in agitation 
and in quality of life amongst individuals with agitation, over 9 months and reduced cost. WHELD therefore has a number 
of advantages compared to pharmacological treatments currently used to treat agitation. 
